On the chart you can see the default numbers in dynamics for Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ). Companys revenue shows the average of 1610.414 M which is 0.378 % gowth. The average gross profit for the whole period is 1335.139 M which is 0.405 %. The average gross profit ratio is 0.795 %. The net income growth for the company last year performance is -7.490 % which equals 1.767 % % on average for the whole company history.,
Diving into the fiscal trajectory of Shenzhen Kangtai Biological Products Co., Ltd., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of 0.094. In the realm of current assets, 300601.SZ clocks in at 5396.004 in the reporting currency. A significant portion of these assets, precisely 1758.938, is held in cash and short-term investments. This segment shows a change of 0.206% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 2696.246, if any, in the reporting currency. This indicates a difference of 32.083% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 2372.216 in the reporting currency. This figure signifies a year_over_year change of 0.112%. Shareholder value, as depicted by the total shareholder equity, is valued at 9541.685 in the reporting currency. The year over year change in this aspect is 0.062%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 2819.227, with an inventory valuation of 772.85, and goodwill valued at 0, if any. The total intangible assets, if present, are valued at 504.24. Account payables and short-term debt are 791.18 and 174.34, respectively. The total debt is 2546.55, with a net debt of 1350.97. Other current liabilities amount to 1757.08, adding to the total liabilities of 5214.97. Lastly, the referred stock is valued at 0, if it exists.
The financial landscape of Shenzhen Kangtai Biological Products Co., Ltd. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of 1.491. The company recently extended its share capital by issuing 132.7, marking a difference of -0.319 compared to the previous year. The company's investing activities resulted in net cash usage, amounting to -2606303997.100 in the reporting currency. This is a shift of 0.810 from the previous year. In the same period, the company recorded 200.95, -2.37, and -1070.44, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated -622.15 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 1115.57, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.
Shenzhen Kangtai Biological Products Co., Ltd.'s revenue saw a change of 0.093% compared with the previous period. The gross profit of 300601.SZ is reported to be 2829.07. The company's operating expenses are 2054.24, showing a change of 1.654% from the last year. The expenses for depreciation and amortization are 200.95, which is a 0.198% change from the last accounting period. Operating expenses are reported to be 2054.24, which shows a 1.654% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a 0.037% year-over-year growth. The operating income is 774.83, which shows a 0.037% change when compared to the previous year. The change in the net income is -7.490%. The net income for the last year was 861.3.
